What we do Shilpa Medicare Ltd is a leading pharmaceutical company specializing in APIs, formulations, biologics including oncology products, biosimilars, CDMO and novel drug delivery systems globally. |
Founded in 1,987 |
Market share Among world's leading suppliers of oncology and non-oncology APIs with significant presence in USA, Europe, India, and emerging markets. |
Problem solved Addresses global demand for affordable, innovative oncology and specialty pharmaceuticals, improving treatment accessibility and novel therapies in markets worldwide. |
Top clients or who we serve Serves global pharma companies, regulatory markets in USA, Europe, Japan, India, and emerging markets; B2B pharmaceutical and biotechnology sectors. |
Key management Vishnukant C. Bhutada (Managing Director) and Kalakota Sharath Reddy (Whole-Time Director) lead the company with extensive industry experience. |
Our journey and innovations Founded in 1987, evolved from API manufacturing to integrated pharma with biosimilars and novel therapies; launched India's first-in-class NAFLD treatment. |
Where we operate Operates in India, USA, Europe, Japan, South Korea, Russia, Brazil, and other emerging markets with multiple manufacturing and R&D facilities. |
Top products or what we offer Oncology APIs like Capecitabine, Gemcitabine; branded generics such as Noduca for NAFLD; biologics including Adalimumab; CDMO and specialty chemicals. |
Top brands Noduca (NAFLD treatment), Ibrushil (Ibrutinib generic), Lenshil (Lenvatinib), Biologicals including High Concentration Adalimumab. |
Raw materials needed Chemical intermediates, fermentation substrates, peptides precursors, specialty compounds for APIs and biological products. |
Raw materials supplier Sourced globally and locally from multiple suppliers ensuring high quality for pharma manufacturing requirements. |
Recurring vs cyclical contribution Majority revenue from recurring API sales, formulations, and CDMO contracts; some cyclical regulatory approvals impact new product launches. |
Our industry position Strong position in oncology APIs globally; growing formulation and biologics segments; recognized for innovation and regulatory compliance. |
Financial highlights FY25 consolidated revenue INR 1,286 crore with net profit INR 78 crore, showing double-digit YoY revenue and profit growth driven by API and formulations. |
Geographical revenue split Revenue mainly from India (37%), Europe (23%), USA (18%), and Rest of World (21%). |
Order book Strong order pipeline in CDMO contracts and formulations with increasing commercial launches. |
Whats driving growth Growth driven by product innovation, capacity expansion in APIs and biologics, regulatory approvals, and strategic partnerships globally. |
Our future plans Focus on biosimilars, novel drug delivery, ADC biologics, expanding R&D, global regulatory filings, and enhancing manufacturing capabilities. |
Our green promise Committed to sustainable manufacturing practices and compliance with environmental regulations at all facilities. |
Our people and values Over 400 R&D personnel fostering innovation with a culture of integrity, scientific excellence, and employee development. |
Key challenges ahead Regulatory hurdles, competition in generics and biosimilars, supply chain disruptions, and maintaining innovation pipeline. |
Interesting facts First global company to obtain NAFLD treatment approval; over 585 patents filed; strategic biologics partnerships including with Orion Corporation. |
Risks and strategy Mitigates regulatory and market risks via diversified product portfolio, strong compliance, and continuous R&D investment. |
